Drug Trial Radar · NCT07389733
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 27, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
Conditions
- Advanced Unresectable or Metastatic Breast Cancer of Adults
Interventions
HRS-6208 CapsuleDrug
HRS-6208 capsule.
HRS-6209 CapsuleDrug
HRS-6209 capsule.
HRS-8080 TabletDrug
HRS-8080 tablet.
Fulvestrant injectionDrug
Fulvestrant injection.
Letrozole tabletsDrug
Letrozole tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: The DLT will be evaluated for the last participant in each dose group 28 days after the first dose.
- Recommended phase II dose (RP2D)Time frame: The evaluation of RP2D will be completed approximately one year later than DLT evaluation.
- Incidence and severity of adverse events (AEs)Time frame: Each individual participant will be followed for approximately 8 months, and the entire study process will last for approximately 36 months.
- Objective response rate (ORR)Time frame: For a single subject, the duration will be approximately 8 months, while the entire research process will last for 36 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.